Sphingosine-1-phosphate receptor modulators in ulcerative colitis - a narrative review of current evidence and practical considerations

Journal article : Review

Ulcerative colitis (UC) is a chronic inflammatory bowel disorder with a relapsing and remitting course often necessitating the use of advanced therapy to maintain disease control. Sphingosine-1-phosphate receptor modulators (S1PRMs) represent a new class of oral small molecules approved for the management of moderate-to-severe UC. Evidence from pivotal trials shows promising results for the induction and maintenance of remission in UC. This comprehensive review of S1PRMs explores their mechanism of action, key clinical trial data, real-world insights, and an overview of their safety, including considerations for special populations and comparative effectiveness. S1PRMs offer distinct advantages, including oral administration and a lack of immunogenicity, positioning them as valuable additions to the UC treatment landscape. However, future research will be required to understand their position in the evolving UC treatment paradigms.

Authors: Kuriakose Kuzhiyanjal, AJ; Sethi-Arora, K; Nigam, GB; Limdi, JK

• Publication status: Published
• Peer review status: Peer reviewed
• Publisher: BioExcel
• Journal: Drugs in context
• Volume: 14
• Pages: 1-19
• Publication date: 2025-12-18
• Acceptance date: 2025-11-14
• DOI: 10.7573/dic.2025-7-3
• ISSN: 1745-1981
• Pmid: 41446438
• Language: English
• Keywords: Inflammatory Bowel Disease; Ulcerative colitis; Sphingosine-1-phosphate; Small molecules; Ozanimod; Etrasimod
• Subtype: Review